Galectin Therapeutics Stock Return On Equity
| GALT Stock | USD 1.59 0.06 3.92% |
Galectin Therapeutics fundamentals help investors to digest information that contributes to Galectin Therapeutics' financial success or failures. It also enables traders to predict the movement of Galectin Stock. The fundamental analysis module provides a way to measure Galectin Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Galectin Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Return On Equity | 0.78 | 0.74 |
Galectin | Return On Equity |
Galectin Therapeutics Company Return On Equity Analysis
Galectin Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Galectin Therapeutics Return On Equity | -37.28 |
Most of Galectin Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Galectin Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Galectin Return On Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Galectin Therapeutics is extremely important. It helps to project a fair market value of Galectin Stock properly, considering its historical fundamentals such as Return On Equity. Since Galectin Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Galectin Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Galectin Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Galectin Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Galectin Therapeutics has a Return On Equity of -37.2795. This is 55.53% higher than that of the Biotechnology sector and 2.25% higher than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Galectin Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Galectin Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Galectin Therapeutics could also be used in its relative valuation, which is a method of valuing Galectin Therapeutics by comparing valuation metrics of similar companies.Galectin Therapeutics is currently under evaluation in return on equity category among its peers.
Galectin Fundamentals
| Return On Equity | -37.28 | ||||
| Return On Asset | -0.97 | ||||
| Current Valuation | 175.77 M | ||||
| Shares Outstanding | 62.76 M | ||||
| Shares Owned By Insiders | 31.13 % | ||||
| Shares Owned By Institutions | 16.26 % | ||||
| Number Of Shares Shorted | 7.72 M | ||||
| Price To Earning | (4.21) X | ||||
| Price To Book | 207.70 X | ||||
| EBITDA | (202 K) | ||||
| Net Income | (41.07 M) | ||||
| Cash And Equivalents | 15.83 M | ||||
| Cash Per Share | 0.27 X | ||||
| Total Debt | 71.81 M | ||||
| Current Ratio | 1.79 X | ||||
| Book Value Per Share | (1.52) X | ||||
| Cash Flow From Operations | (32.97 M) | ||||
| Short Ratio | 31.28 X | ||||
| Earnings Per Share | (0.76) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 14 | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 99.79 M | ||||
| Total Asset | 28.2 M | ||||
| Retained Earnings | (354.37 M) | ||||
| Working Capital | 12.03 M | ||||
| Current Asset | 26.4 M | ||||
| Current Liabilities | 1.36 M | ||||
| Net Asset | 28.2 M |
About Galectin Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Galectin Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Galectin Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Galectin Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.